[go: up one dir, main page]

BR112016022727A8 - imunorreceptores específicos de claudina-6 e epítopos de células t - Google Patents

imunorreceptores específicos de claudina-6 e epítopos de células t Download PDF

Info

Publication number
BR112016022727A8
BR112016022727A8 BR112016022727A BR112016022727A BR112016022727A8 BR 112016022727 A8 BR112016022727 A8 BR 112016022727A8 BR 112016022727 A BR112016022727 A BR 112016022727A BR 112016022727 A BR112016022727 A BR 112016022727A BR 112016022727 A8 BR112016022727 A8 BR 112016022727A8
Authority
BR
Brazil
Prior art keywords
claudin
cell epitopes
immunoreceptors
specific immunoreceptors
specific
Prior art date
Application number
BR112016022727A
Other languages
English (en)
Other versions
BR112016022727B1 (pt
BR112016022727A2 (pt
Inventor
Breitkreuz Andrea
Hoff Holger
Anna Mroz Karolina
Hobohm Kathleen
Simon Petra
Voss Ralf-Holger
Omokoko Tana
Sahin Ugur
Türeci Özlem
Original Assignee
Biontech Cell & Gene Therapies Gmbh
Ganymed Pharmaceuticals Ag
Tron Translationale Onkologie An Der Univ Der Johannes Gutenberg Univ Mainz Gemeinnuetzige Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52745896&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112016022727(A8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biontech Cell & Gene Therapies Gmbh, Ganymed Pharmaceuticals Ag, Tron Translationale Onkologie An Der Univ Der Johannes Gutenberg Univ Mainz Gemeinnuetzige Gmbh filed Critical Biontech Cell & Gene Therapies Gmbh
Publication of BR112016022727A2 publication Critical patent/BR112016022727A2/pt
Publication of BR112016022727A8 publication Critical patent/BR112016022727A8/pt
Publication of BR112016022727B1 publication Critical patent/BR112016022727B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/428—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3007—Carcino-embryonic Antigens
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/59—Reproductive system, e.g. uterus, ovaries, cervix or testes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)

Abstract

a presente invenção fornece imunorreceptores específicos de claudina-6(receptores de células t e receptores artificiais de células t (receptores antigênicos quiméricos; cars)) e epítopos de células t que são úteis para uma imunoterapia.
BR112016022727-1A 2014-04-01 2015-03-30 Receptor artificial de células t, método de produzir uma célula imunorreativa, composição farmacêutica, uso da composição farmacêutica, e uso do receptor artificial de células t BR112016022727B1 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP2014000868 2014-04-01
EPPCT/EP2014/000868 2014-04-01
EPPCT/EP2014/072864 2014-10-24
EP2014072864 2014-10-24
PCT/EP2015/056899 WO2015150327A1 (en) 2014-04-01 2015-03-30 Claudin-6-specific immunoreceptors and t cell epitopes

Publications (3)

Publication Number Publication Date
BR112016022727A2 BR112016022727A2 (pt) 2017-10-31
BR112016022727A8 true BR112016022727A8 (pt) 2018-12-04
BR112016022727B1 BR112016022727B1 (pt) 2025-05-06

Family

ID=

Also Published As

Publication number Publication date
SI3126381T2 (sl) 2022-05-31
HUE067504T2 (hu) 2024-10-28
RS65784B1 (sr) 2024-08-30
SI3126381T1 (sl) 2019-07-31
HRP20190472T4 (hr) 2022-06-24
JP2020096630A (ja) 2020-06-25
RS58627B1 (sr) 2019-05-31
ES2717530T5 (es) 2022-05-06
SMT201900262T1 (it) 2019-07-11
JP2022046462A (ja) 2022-03-23
JP6726656B2 (ja) 2020-07-22
PT3514172T (pt) 2020-04-21
US11345731B2 (en) 2022-05-31
HUE044515T2 (hu) 2019-10-28
PT3708579T (pt) 2024-07-17
SI3514172T1 (sl) 2020-07-31
CN113150110A (zh) 2021-07-23
CA2942459C (en) 2023-03-07
AU2021203528B2 (en) 2022-10-13
NZ723544A (en) 2021-10-29
PL3126381T5 (pl) 2022-05-23
JP6985440B2 (ja) 2021-12-22
HUE050355T2 (hu) 2020-12-28
AU2019210582B2 (en) 2021-03-04
AU2021203528A1 (en) 2021-07-01
RS58627B2 (sr) 2022-06-30
DK3708579T3 (da) 2024-07-22
AU2019210582A1 (en) 2019-08-22
CN106459165A (zh) 2017-02-22
PT3126381T (pt) 2019-04-18
DK3126381T3 (en) 2019-04-15
US20190389920A1 (en) 2019-12-26
WO2015150327A1 (en) 2015-10-08
MX2016012713A (es) 2018-03-01
JP2017518762A (ja) 2017-07-13
MX376026B (es) 2025-03-07
US10370423B2 (en) 2019-08-06
EP3126381B2 (en) 2022-02-16
EP3514172A1 (en) 2019-07-24
ES2717530T3 (es) 2019-06-21
CY1121539T1 (el) 2020-05-29
PL3708579T3 (pl) 2024-08-05
JP7451858B2 (ja) 2024-03-19
LT3126381T (lt) 2019-05-27
ES2784537T3 (es) 2020-09-28
AU2015239683B2 (en) 2019-08-22
EP3126381B1 (en) 2019-01-16
CA2942459A1 (en) 2015-10-08
HRP20190472T1 (hr) 2019-06-14
PL3126381T3 (pl) 2019-09-30
AU2015239683A1 (en) 2016-09-08
US20170015720A1 (en) 2017-01-19
LT3708579T (lt) 2024-07-25
EP3708579A1 (en) 2020-09-16
PL3514172T3 (pl) 2020-07-27
EP3708579B1 (en) 2024-05-01
CN113150109A (zh) 2021-07-23
EP3514172B1 (en) 2020-03-11
CN106459165B (zh) 2021-04-20
SI3708579T1 (sl) 2024-09-30
US20220306711A1 (en) 2022-09-29
ES2982838T3 (es) 2024-10-17
ME03407B (me) 2020-01-20
BR112016022727A2 (pt) 2017-10-31
EP3126381A1 (en) 2017-02-08
DK3514172T3 (da) 2020-04-06
DK3126381T4 (da) 2022-04-04
HRP20240926T1 (hr) 2024-10-11
FI3708579T3 (fi) 2024-07-16

Similar Documents

Publication Publication Date Title
MX2022000132A (es) Inmunoreceptores especificos de claudina-18.2 y epitopos de celulas t.
MX376026B (es) Inmunoreceptores especificos de claudina-6 y epitopos de celulas t.
CY1125032T1 (el) Υποκινητης mnd χιμαιρικους υποδοχεις αντιγονου
CL2018001556A1 (es) Receptores de antígenos quiméricos (car) de bcma. (solicitud divisional 201701515)
IL260151A (en) T cell receptors specific for the ny-eso-1 tumor antigen-hla-a 02 complex
MX2017001079A (es) Receptores de antígeno quiméricos de antígeno de maduración de células b (bcma).
CL2016001871A1 (es) Anticuerpos humanos para pd-1
CL2017001408A1 (es) Anticuerpos anti-cd79b y métodos de uso
CL2017000590A1 (es) Anticuerpos anti-cll-1 e inmunoconjugados
IL252937A0 (en) Anti-cll1 specific single-chain chimeric antigen receptors (sccars) for cancer immunotherapy
IL250161B (en) Ror1-specific chimeric antigen receptors (ntrkr1) for cancer immunotherapy
LT3183268T (lt) Anti-cd123 chimerinis antigeno receptorius (car), skirtas naudoti vėžio gydymui
CR20170131A (es) Anticuerpos anti-her2 e inmunoconjugados
CL2017001461A1 (es) Composiciones y métodos para anticuerpos que se marcan bmp6
EA201791029A1 (ru) Антитела против интерлейкина-33 и их применение
MX2017001597A (es) Anticuerpos anti-pd-l1.
EP3198010A4 (en) Glypican-3 specific chimeric antigen receptors for adoptive immunotherapy
GB201511191D0 (en) T-cell epitopes for the immunotherapy of myeloma
EP3237439A4 (en) Compositions and methods for generating antigens, antibodies, and immunotherapeutic compositions and methods
MX2016010433A (es) Anticuerpos anti-jagged1 y metodos de uso.
BR112018006991A2 (pt) receptores de antígeno quiméricos direcionados ao psca
EP3705494A3 (en) Antibodies against frizzled proteins and methods of use thereof
EP3518973A4 (en) NEUTRALIZING ANTIBODIES AGAINST THE ALPHA V BETA 8 INTEGRIN COMPLEX FOR IMMUNOTHERAPY
MX2016016233A (es) Anticuerpos anti-lgr5 y sus usos.
EP3231441A4 (en) Novel protein structure produced by effective antibody used for immunization

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NAO 10196/2001, QUE MODIFICOU A LEI NAO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUAANCIA PRA VIA DA ANVISA. CONSIDERANDO A APROVAA AO DOS TERMOS DO PARECER NAO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NAO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDAANCIAS CABA-VEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B154 Notification of filing of divisional application [chapter 15.50 patent gazette]

Free format text: O PEDIDO FOI DIVIDIDO NO BR122024004256-8 PROTOCOLO 870240017920 EM 01/03/2024 19:11.

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B25D Requested change of name of applicant approved

Owner name: BIONTECH CELL AND GENE THERAPIES GMBH (DE) ; TRON -TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITAETSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITAET MAINZ GEMEINNUETZIGE GMBH (DE) ; GANYMED PHARMACEUTICALS GMBH (DE)

B25G Requested change of headquarter approved

Owner name: BIONTECH CELL AND GENE THERAPIES GMBH (DE) ; TRON -TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITAETSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITAET MAINZ GEMEINNUETZIGE GMBH (DE) ; GANYMED PHARMACEUTICALS GMBH (DE)

B25A Requested transfer of rights approved

Owner name: BIONTECH CELL AND GENE THERAPIES GMBH (DE) ; TRON -TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITAETSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITAET MAINZ GEMEINNUETZIGE GMBH (DE) ; ASTELLAS PHARMA INC. (JP)

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 30/03/2015, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.

B09W Correction of the decision to grant [chapter 9.1.4 patent gazette]

Free format text: RETIFICACAO DA CARTA PATENTE CONCEDIDA, DESPACHO CODIGO 16.1, RPI NO 2835 DE 06/05/2025. POR MEIO DE SOLICITACAO VIA FALE CONOSCO, MENSAGEM 1333747 DE 14/05/2025, FOI APRESENTADO NOVO QUADRO REIVINDICATORIO EM SUBSTITUICAO AO SUBMETIDO POR MEIO DA PETICAO 870240057025 DE 05/07/2024 (AO QUAL FOI CONFERIDO O DEFERIMENTO, 9.1 RPI 2829 DE 25/03/2025) PARA CORRECAO DE ERRO MATERIAL NA REIVINDICACAO 8, NA QUAL ONDE CONSTA O NUMERO ?7? DEVERIA CONSTAR ?5?. APOS A VERIFICACAO, A SOLICITACAO FOI APROVADA. ASSIM RETIFICA-SE A REFERIDA PUBLICACAO COM O QUADRO 1 CORRIGIDO

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: REF. RPI 2835 DE 06/05/2025 QUANTO AO QUADRO REIVINDICATORIO POR ERRO MATERIAL DO INTERESSADO.